Legal & General Group
ABUS icon

Legal & General Group’s Arbutus Biopharma ABUS Stock Holding History

Legal & General Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
2,466,127
+64,738
+3% +$284K ﹤0.01% 1094
2026
Q1 		$10.8M Buy
2,401,389
+2,278,628
+1,856% +$9.96M ﹤0.01% 1080
2025
Q4 		$590K Sell
122,761
-1,416
-1% -$6.37K ﹤0.01% 2371
2025
Q3 		$564K Sell
124,177
-309
-0.2% -$1.14K ﹤0.01% 2411
2025
Q2 		$385K Buy
124,486
+6,089
+5% +$20.2K ﹤0.01% 2516
2025
Q1 		$413K Sell
118,397
-296
-0.2% -$987 ﹤0.01% 2456
2024
Q4 		$388K Sell
118,693
-27,104
-19% -$99.7K ﹤0.01% 2548
2024
Q3 		$561K Buy
145,797
+130,549
+856% +$501K ﹤0.01% 2425
2024
Q2 		$47.1K Buy
15,248
+2,940
+24% +$8.82K ﹤0.01% 2803
2024
Q1 		$31.8K Hold
12,308
– – ﹤0.01% 2843
2023
Q4 		$30.8K Hold
12,308
– – ﹤0.01% 2888
2023
Q3 		$25K Sell
12,308
-1,749
-12% -$3.67K ﹤0.01% 2959
2023
Q2 		$32.3K Buy
14,057
+1,859
+15% +$4.84K ﹤0.01% 2948
2023
Q1 		$37K Hold
12,198
– – ﹤0.01% 2927
2022
Q4 		$28.4K Hold
12,198
– – ﹤0.01% 3068
2022
Q3 		$23K Buy
12,198
+1,732
+17% +$4.08K ﹤0.01% 3165
2022
Q2 		$28K Buy
10,466
+2,515
+32% +$6.44K ﹤0.01% 3125
2022
Q1 		$24K Buy
7,951
+1,426
+22% +$4.37K ﹤0.01% 3180
2021
Q4 		$25K Hold
6,525
– – ﹤0.01% 3196
2021
Q3 		$28K Buy
6,525
+284
+5% +$946 ﹤0.01% 3145
2021
Q2 		$19K Buy
+6,241
New +$19.3K ﹤0.01% 3305
2019
Q3 		– Sell
-5,247
Closed -$11K – 3349
2019
Q2 		$11K Hold
5,247
– – ﹤0.01% 3339
2019
Q1 		$19K Sell
5,247
-23,160
-82% -$88.9K ﹤0.01% 3104
2018
Q4 		$109K Buy
28,407
+3,867
+16% +$19K ﹤0.01% 2431
2018
Q3 		$232K Buy
24,540
+19,293
+368% +$192K ﹤0.01% 2304
2018
Q2 		$38K Buy
+5,247
New +$31.2K ﹤0.01% 2887

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Legal & General Group's ABUS Position: Q2 2026 in Review

Legal & General Group increased its Arbutus Biopharma (ABUS) stake by 2.7% in Q2 2026, buying an estimated $284K and bringing the position to 2,466,127 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Legal & General Group first reported a position in ABUS in Q2 2018 and has held it in 26 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Legal & General Group held 2,466,127 shares of Arbutus Biopharma worth $11.8M as of Q2 2026.
  • Legal & General Group bought 64,738 Arbutus Biopharma shares in Q2 2026, an estimated $284K.
  • Arbutus Biopharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1094 holding.
  • Legal & General Group first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 26 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.